FLHLF / Filament Health's expertise positions it to tap into multi-billion psychedelics opportunity

Analysts at Water Tower Research have initiated coverage on Filament Health Corp (OTCQB:FLHLF, NEO:FH) with a positive outlook on the firm which they more_horizontal

Filament Health Corp (OTCQB:FLHLF, NEO:FH) said Magdalena Biosciences, its joint venture (JV) with Jaguar Health, has initiated a preclinical study o more_horizontal

Filament Health Corp (OTCQB:FLHLF, NEO:FH) told investors that Health Canada has approved a phase 2 clinical trial of its botanical psilocybin drug ca more_horizontal

Biotechnology companies researching the therapeutic potential of various psychedelics are choosing to work with natural forms of these compounds deriv more_horizontal

With MDMA on track to gain United States Food and Drug Administration (FDA) approval for the treatment of post-traumatic stress disorder (PTSD) in 202 more_horizontal

Filament Health Corp (OTCQB:FLHLF, NEO:FH) told investors it intends to complete a non-brokered private placement for gross proceeds of up to C$2 mil more_horizontal

Filament Health Corp (OTCQB:FLHLF)'s diversified business model makes it one of the only psychedelics companies to be already generating revenue.   more_horizontal

Filament Health Corp (OTCQB:FLHLF) told investors that its Magdalena Biosciences joint venture (JV) with Jaguar Health has completed an import of coca more_horizontal